CA2365405A1 - Recepteur tr2 du facteur de necrose tumorale chez l'homme - Google Patents

Recepteur tr2 du facteur de necrose tumorale chez l'homme Download PDF

Info

Publication number
CA2365405A1
CA2365405A1 CA002365405A CA2365405A CA2365405A1 CA 2365405 A1 CA2365405 A1 CA 2365405A1 CA 002365405 A CA002365405 A CA 002365405A CA 2365405 A CA2365405 A CA 2365405A CA 2365405 A1 CA2365405 A1 CA 2365405A1
Authority
CA
Canada
Prior art keywords
seq
amino acid
polypeptides
sequence
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002365405A
Other languages
English (en)
Inventor
Jian Ni
Craig A. Rosen
Reiner L. Gentz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Human Genome Sciences Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2365405A1 publication Critical patent/CA2365405A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/026—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La présente invention concerne de nouveaux membres de la famille des récepteurs du facteur de nécrose tumorale. L'invention concerne des molécules isolées d'acide nucléique codant un récepteur TR2 humain et deux variantes épissées dudit récepteur. L'invention concerne aussi des polypeptides TR2, ainsi que des vecteurs, cellules hôtes et procédés de recombinaison permettant de produire lesdits éléments. L'invention concerne également des méthodes de sélection permettant d'identifier des agonistes et antagonistes de l'activité du récepteur TR2. L'invention concerne en outre des méthodes diagnostiques pour dépister des pathologies liées à l'expression aberrante de récepteurs TR2, ainsi que des méthodes thérapeutiques pour traiter des pathologies liées à une prolifération ou différenciation aberrante de cellules exprimant des récepteurs TR2.
CA002365405A 1999-03-22 2000-03-22 Recepteur tr2 du facteur de necrose tumorale chez l'homme Abandoned CA2365405A1 (fr)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US12568399P 1999-03-22 1999-03-22
US60/125,683 1999-03-22
US12652299P 1999-03-26 1999-03-26
US60/126,522 1999-03-26
US13516999P 1999-05-20 1999-05-20
US60/135,169 1999-05-20
US14738399P 1999-08-06 1999-08-06
US60/147,383 1999-08-06
PCT/US2000/007521 WO2000056405A2 (fr) 1999-03-22 2000-03-22 Recepteur tr2 du facteur de necrose tumorale chez l'homme

Publications (1)

Publication Number Publication Date
CA2365405A1 true CA2365405A1 (fr) 2000-09-28

Family

ID=27494596

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002365405A Abandoned CA2365405A1 (fr) 1999-03-22 2000-03-22 Recepteur tr2 du facteur de necrose tumorale chez l'homme

Country Status (5)

Country Link
EP (1) EP1165185A2 (fr)
JP (1) JP2002540083A (fr)
AU (1) AU3766700A (fr)
CA (1) CA2365405A1 (fr)
WO (1) WO2000056405A2 (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030068619A1 (en) * 2001-07-27 2003-04-10 Lal Preeti G. TNF receptor 2 related protein variant
WO2003011321A1 (fr) * 2001-07-31 2003-02-13 Genset S.A. Agonistes et antagonistes de la cobesine pour le traitement des troubles metaboliques
CA2605253C (fr) * 2005-04-11 2017-06-13 Yale University Modulation selective de recepteurs du facteur de necrose tumorale en therapie
WO2012048275A2 (fr) 2010-10-08 2012-04-12 Caridianbct, Inc. Procédés et systèmes configurables pour la culture et la récolte de cellules dans un système de bioréacteur à fibres creuses
EP3068867B1 (fr) 2013-11-16 2018-04-18 Terumo BCT, Inc. Expansion de cellules dans un bioréacteur
EP3122866B1 (fr) 2014-03-25 2019-11-20 Terumo BCT, Inc. Remplacement passif de milieu
CN106715676A (zh) 2014-09-26 2017-05-24 泰尔茂比司特公司 按计划供养
EP3277727B1 (fr) * 2015-04-02 2021-11-03 Memorial Sloan Kettering Cancer Center Protéines de tnfrsf14/hvem et leurs procédés d'utilisation
WO2017004592A1 (fr) 2015-07-02 2017-01-05 Terumo Bct, Inc. Croissance cellulaire à l'aide de stimuli mécaniques
EP3464565A4 (fr) 2016-05-25 2020-01-01 Terumo BCT, Inc. Expansion cellulaire
US11685883B2 (en) 2016-06-07 2023-06-27 Terumo Bct, Inc. Methods and systems for coating a cell growth surface
US11104874B2 (en) 2016-06-07 2021-08-31 Terumo Bct, Inc. Coating a bioreactor
US11624046B2 (en) 2017-03-31 2023-04-11 Terumo Bct, Inc. Cell expansion
CN117247899A (zh) 2017-03-31 2023-12-19 泰尔茂比司特公司 细胞扩增

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0486526T3 (da) * 1989-08-07 1996-06-24 Peptide Technology Ltd Bindingsligander for tumornekrosefaktor
AU703091B2 (en) * 1995-08-04 1999-03-18 Lek Tovarna Farmacevtskih In Kemicnih Izdelkov, D.D. Monoclonal antibodies against soluble TNF-alpha receptors p55 and p75 as well as against TNF-alpha and its analogues
CA2290067A1 (fr) * 1997-05-12 1998-11-19 Smithkline Beecham Corporation Anticorps contre le recepteur de type 2 (tr2) du facteur de necrose des tumeurs humain

Also Published As

Publication number Publication date
EP1165185A2 (fr) 2002-01-02
JP2002540083A (ja) 2002-11-26
AU3766700A (en) 2000-10-09
WO2000056405A2 (fr) 2000-09-28
WO2000056405A3 (fr) 2001-01-04

Similar Documents

Publication Publication Date Title
US7824675B2 (en) Use of an antibody that binds human tumor necrosis factor receptor-like 2
US6406867B1 (en) Antibody to human endokine alpha and methods of use
US7452538B2 (en) Death domain containing receptor 4 antibodies and methods
US7476384B2 (en) Death domain containing receptor 4 antibody and methods
US6872568B1 (en) Death domain containing receptor 5 antibodies
US8329179B2 (en) Death domain containing receptor 4 antibodies and methods
US6689607B2 (en) Human tumor, necrosis factor receptor-like proteins TR11, TR11SV1 and TR11SV2
US20020187526A1 (en) Neutrokine-alpha binding proteins and methods based thereon
US7708996B2 (en) DR3 antibodies
US20040136951A1 (en) Death domain containing receptor 5
US20080248046A1 (en) Death domain containing receptor 5
US6635743B1 (en) Apoptosis inducing molecule II and methods of use
US20050233958A1 (en) Death domain containing receptor 5
CA2365405A1 (fr) Recepteur tr2 du facteur de necrose tumorale chez l'homme
JP2010252803A (ja) ヒトエンドカインαおよび使用方法
US20070160595A1 (en) Human Tumor Necrosis Factor TR20 and Methods Based Thereon
WO2000066156A1 (fr) Recepteur 5 contenant le domaine de l'apoptose
EP1161261A1 (fr) Molecule ii induisant l'apoptose et techniques d'utilisation
CA2413160A1 (fr) Facteur de necrose tumorale humain delta et epsilon
US7964190B2 (en) Methods and compositions for decreasing T-cell activity
US20020106736A1 (en) Human tumor necrosis factor receptor TR17

Legal Events

Date Code Title Description
FZDE Discontinued